KRAS and neoplasm: However, in multivariate analysis, the presence of a G12D and/or G12C mutation in the tumor was the only factor significantly associated with a lower PFS when compared with other KRAS status (i.e., WT, G12R and G12V mutations) (HR 1.792, 95% CI 1.061–3.028, p = 0.029).